Reliability and validity of cutaneous sarcoidosis outcome instruments among dermatologists, pulmonologists, and rheumatologists

JAMA Dermatology

Volumn 151, Issue 12, 2015, Pages 1317-1322

  Yeung, Howa ^a   Farber, Sara ^b   Birnbaum, Belinda K ^c   Dunham, Jonathan ^c   Ogdie, Alexis ^c   Patterson, Karen C ^c   Payne, Aimee S ^b   Porteous, Mary K ^c   Rossman, Milton D ^c   Sharim, Rebecca ^c   Takeshita, Junko ^c   Werth, Victoria P ^b   Shin, Daniel B ^c   Price, Sarah ^b   Rosenbach, Misha ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CLINICAL ARTICLE; CLINICAL FEATURE; CONFERENCE PAPER; CONSTRUCT VALIDITY; CONTROLLED STUDY; CONVERGENT VALIDITY; CORRELATION COEFFICIENT; CROSS-SECTIONAL STUDY; CUTANEOUS PARAMETERS; CUTANEOUS SARCOIDOSIS ACTIVITY AND MORPHOLOGY INSTRUMENT ACTIVITY SCALE; DERMATOLOGIST; DISEASE SEVERITY; FEMALE; HUMAN; INTERRATER RELIABILITY; INTRARATER RELIABILITY; MALE; OUTCOME ASSESSMENT; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PULMONOLOGIST; QUALITY OF LIFE INDEX; RELIABILITY; RHEUMATOLOGY; SARCOIDOSIS; SARCOIDOSIS ACTIVITY AND SEVERITY INDEX; SCORING SYSTEM; SKIN STIGMA RAW SCORE; VALIDITY;

EID: 84949642267     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.2008     Document Type: Conference Paper

References (25)

1. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153-2165.
2. Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist, part I: cutaneous disease. J AmAcad Dermatol. 2012;66(5):699.e1-699.e18. doi:10.1016/j.jaad.2011.11.965.
3. Judson MA, Baughman RP, Costabel U, et al; Centocor T48 Sarcoidosis Investigators. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31(6): 1189-1196.
4. Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765-773.
5. Drake WP, Oswald-Richter K, Richmond BW, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol. 2013;149(9):1040-1049.
6. Droitcourt C, Rybojad M, Porcher R, et al. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. Chest. 2014;146(4):1046-1054.
7. Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296-1307.
8. Baughman RP, Judson MA, Teirstein A, et al. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol. 2008;9(3):155-161.
9. Rosenbach M, Yeung H, Chu EY, et al. Reliability and convergent validity of the Cutaneous Sarcoidosis Activity and Morphology Instrument for assessing cutaneous sarcoidosis. JAMA Dermatol. 2013;149(5):550-556.
10. Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol. 2012;148(2):262-264.
11. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433-1440.
12. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216.
13. Judson MA, Mack M, Beaumont JL,Watt R, Barnathan ES, Victorson DE. Validation and important differences for the Sarcoidosis Assessment Tool: a new patient-reported outcome measure. Am J Respir Crit Care Med. 2015;191(7): 786-795.
14. Rosenbach M, Murrell DF, Bystryn JC, et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol. 2009;129(10):2404-2410.
15. Goreshi R, Okawa J, Rose M, et al. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dermatol. 2012;132(4): 1117-1124.
16. Victorson DE, Choi S, Judson MA, Cella D. Development and testing of item response theory-based item banks and short forms for eye, skin and lung problems in sarcoidosis. Qual Life Res. 2014;23(4):1301-1313.
17. Victorson DE, Cella D, Grund H, Judson MA. A conceptual model of health-related quality of life in sarcoidosis. Qual Life Res. 2014;23(1):89-101.
18. Gourraud PA, Le Gall C, Puzenat E, Aubin F, Ortonne JP, Paul CF.Why statistics matter: limited inter-rater agreement prevents using the Psoriasis Area and Severity Index as a unique determinant of therapeutic decision in psoriasis. J Invest Dermatol. 2012;132(9):2171-2175.
19. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979; 86(2):420-428.
20. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull. 1971;76(5):378-382.
21. Mezzich JE, Kraemer HC,Worthington DR, Coffman GA. Assessment of agreement among several raters formulating multiple diagnoses. J Psychiatr Res. 1981;16(1):29-39.
22. ReichenheimME. Confidence intervals for the kappa statistic. Stata J. 2004;4(4):421-428.
23. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174.
24. Krathen MS, Dunham J, Gaines E, et al. The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. Arthritis Rheum. 2008;59(3): 338-344.
25. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis? quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933-943.